The word "biopharmaceutical" is correct and usable in written English.
You can use it to refer to medicines, drugs, or other substances derived from living organisms or their components. For example, "The research team is focusing on developing new biopharmaceuticals to treat cancer."
Kiran Mazumdar-Shaw, boss of Biocon, an Indian biopharmaceutical company, describes a similar progression: "In the early days, we were taken with a big pinch of salt in India.
The biopharmaceutical revolution has barely begun.Meanwhile, between them, private companies, government agencies and venture-capital firms around the world will pour $4 billion into nanotech innovations this year.
Jeffrey Kindler, who has led the world's biggest drug company since 2006, will be replaced by 32-year Pfizer veteran Ian Read, who is currently the head of biopharmaceutical operations.
The social media messages falsely stated the biopharmaceutical company had tainted drug trial results and a US government agency had seized documentation as a result.
The auguries are also dim: 84 per cent of the participants at a recent biopharmaceutical conference in Monaco view funding as the industry's prime challenge.
In addition to the animal toxicity studies outlined above, biopharmaceutical studies are required for all new drugs.
The government's indictment alleges that Shkreli deceived investors in hedge funds that he ran prior to founding Turing, and that he paid some of his hedge-fund investors back with money that he took from Retrophin, a biopharmaceutical company he started in 2011.
Earlier this year, the stock price of Sarepta Therapeutics, a biopharmaceutical company, dropped 9.9 per cent almost instantly after it was the victim of a Twitter hoax — one day after a similar hoax took shares of Audience Inc. down more than twenty-five per cent.
DDB Remedy will have about a dozen employees, Mr. Lannino said, and is already working for "two major clients, one a pharmaceutical company and the other a biopharmaceutical company working in the oncology field".
Sanofi-Aventis has begun merger negotiations with the biopharmaceutical firm Genzyme after sending a letter outlining a potential takeover worth up to $18.7 billion, people briefed on the matter said Monday.
Sanofi approached Genzyme, one of the nation's biggest biopharmaceutical drug makers, earlier this year about a potential combination, one that would bolster Sanofi's drug pipeline and significantly increase its presence in the sector.
